

MEETING AGENDA

Cancer Immunotherapy: Where to Go Next

The Banbury Center, Cold Spring Harbor Laboratory, New York, USA March 16-19, 2019

This meeting was funded by **Genentech** and **Cold Spring Harbor Laboratory** with additional support from **AbbVie**

Organizers:

Ira Mellman, Genentech Miriam Merad, Icahn School of Medicine at Mount Sinai

This Banbury meeting convened experts to critically review the mechanisms that control tumor response, or underlie the lack of response to current immunotherapy agents. Key themes included: main regulatory pathways that limit antitumor immunity; clinical benefit of novel immunotherapy agents alone or in combination; and novel approaches to accurately assess clinical and biomarker responses and the fundamental features of cancer immunity.

SATURDAY, MARCH 16

AfternoonParticipant arrivals6:00 pmReception, dinner at Robertson House

SUNDAY, MARCH 17

7:15 am	Breakfast at Robertson House
8:30 am	Welcoming and Introductory Remarks Rebecca Leshan, The Banbury Center, Cold Spring Harbor Laboratory Ira Mellman, Genentech, South San Francisco, USA Miriam Merad, Icahn School of Medicine at Mount Sinai, New York, USA
8:45 am	SESSION 1: Resistance Mechanisms to Current Checkpoint Inhibitors Rafi Ahmed, Emory University, Atlanta, USA Nir Hacohen, Massachusetts General Hospital, Boston, USA



10:15 am SESSION 2: Tumor Antigen Immunity

Drew Pardoll, Johns Hopkins University, Baltimore, USA Robert Seder, National Institute of Allergy and Infectious Disease, Bethesda, USA Lélia Delamarre, Genentech, South San Francisco, USA Ugur Sahin, University Medical Center, Mainz, Germany

- 12:30 pm Luncheon at Robertson House
- 2:15 pm SESSION 3: Tumor Microenvironment Modulation of Tumor Immunity Diether Lambrechts, VIB-KU Leuven Center for Cancer Biology, Leuven, Belgium Miriam Merad, Icahn School of Medicine at Mount Sinai, New York, USA Sandra Demaria, Weill Cornell Medicine, New York, USA David Tuveson, Cold Spring Harbor Laboratory, Cold Spring Harbor, USA

6:00 pm Reception, dinner at Robertson House

MONDAY, MARCH 18

	7:15 am	Breakfast at Robertson I	House
--	---------	--------------------------	-------

- 8:30 am SESSION 4: Immune Cell Engineering Michel Sadelain, Memorial Sloan Kettering Cancer Center, New York, USA Brian Brown, Icahn School of Medicine at Mount Sinai, New York, USA
- 10:15 am SESSION 5: Microbiome: Biomarker or Therapeutic Immunity Giorgio Trinchieri, National Cancer Institute, Bethesda, USA Laurence Zitvogel, Gustave Roussy, Villejuif, France
- 12:00 pm Luncheon at Robertson House
- 1:30 pm SESSION 6: Systems Understanding of Therapeutic Immunity Dana Pe'er, Sloan Kettering Institute, New York, USA James Heath, Institute for Systems Biology, Seattle, USA Benjamin Greenbaum, Icahn School of Medicine at Mount Sinai, New York, USA
- 4:00 pm SESSION 7: Beyond Checkpoint Inhibitors Ira Mellman, Genentech, South San Francisco, USA
- 4:30 pm SESSION 8: Meeting Conclusions and Next Steps
- 6:00 pm Reception, dinner at Robertson House



MEETING PARTICIPANTS

Rafi Ahmed, Emory University Brian Brown, Icahn School of Medicine at Mount Sinai Lélia Delamarre, Genentech Sandra Demaria, Weill Cornell Medicine Benjamin Greenbaum, Icahn School of Medicine at Mount Sinai Nir Hacohen, Massachusetts General Hospital James Heath, Institute for Systems Biology Alice Kamphorst, Icahn School of Medicine at Mount Sinai Ephraim Kenigsberg, Icahn School of Medicine at Mount Sinai Diether Lambrechts, VIB-KU Leuven Center for Cancer Biology Ira Mellman, Genentech Miriam Merad, Icahn School of Medicine at Mount Sinai Drew Pardoll, Johns Hopkins University Dana Pe'er, Sloan Kettering Institiute Michel Sadelain, Memorial Sloan Kettering Cancer Center Ugur Sahin, University Medical Center, Mainz Robert Seder, National Institute of Allergy and Infectious Disease Brian Topp, Merck & Co Giorgio Trinchieri, National Cancer Institute David Tuveson, Cold Spring Harbor Laboratory Ursula Weiss, Nature Laurence Zitvogel, Gustave Roussy